Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
Nanduri S, Pilishvili T, Derado G, Soe M, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Link-Gelles R, Jernigan J, Budnitz D, Bell J, Benin A, Shang N, Edwards J, Verani J, Schrag S. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021. MMWR Morbidity And Mortality Weekly Report 2021, 70: 1163-1166. PMID: 34437519, PMCID: PMC8389386, DOI: 10.15585/mmwr.mm7034e3.Peer-Reviewed Original ResearchConceptsNational Healthcare Safety NetworkSARS-CoV-2 infectionNursing home residentsLong-term care facility residentsMRNA COVID-19 vaccineCOVID-19 vaccineVaccine effectivenessCare facility residentsHome residentsDelta variantPfizer-BioNTechModerna vaccineMRNA vaccinesFacility residentsNursing homesCDC's National Healthcare Safety NetworkPreventing SARS-CoV-2 InfectionSevere COVID-19-associated outcomesVaccine-induced immunityNursing home staff membersProtective immune responseCOVID-19 prevention strategiesWeekly reportsEmergency use authorizationSkilled nursing facilities